• Home
  • Politics
  • Health
  • World
  • Business
  • Finance
  • Tech
  • More
    • Sports
    • Entertainment
    • Lifestyle
What's Hot

Three Treatment Options To Consider

May 9, 2025

Microsoft Bans Employees From Using ‘Chinese Propaganda’ Chatbot

May 9, 2025

How Smart Mattresses Improve Sleep Quality For Couples

May 9, 2025
Facebook Twitter Instagram
  • Contact
  • Privacy Policy
  • Terms & Conditions
Saturday, May 10
Patriot Now NewsPatriot Now News
  • Home
  • Politics

    Security video shows brazen sexual assault of California woman by homeless man

    October 24, 2023

    Woman makes disturbing discovery after her boyfriend chases away home intruder who stabbed him

    October 24, 2023

    Poll finds Americans overwhelmingly support Israel’s war on Hamas, but younger Americans defend Hamas

    October 24, 2023

    Off-duty pilot charged with 83 counts of attempted murder after allegedly trying to shut off engines midflight on Alaska Airlines

    October 23, 2023

    Leaked audio of Shelia Jackson Lee abusively cursing staffer

    October 22, 2023
  • Health

    Disparities In Cataract Care Are A Sorry Sight

    October 16, 2023

    Vaccine Stocks—Including Pfizer, Moderna, BioNTech And Novavax—Slide Amid Plummeting Demand

    October 16, 2023

    Long-term steroid use should be a last resort

    October 16, 2023

    Rite Aid Files For Bankruptcy With More ‘Underperforming Stores’ To Close

    October 16, 2023

    Who’s Still Dying From Complications Related To Covid-19?

    October 16, 2023
  • World

    New York Democrat Dan Goldman Accuses ‘Conservatives in the South’ of Holding Rallies with ‘Swastikas’

    October 13, 2023

    IDF Ret. Major General Describes Rushing to Save Son, Granddaughter During Hamas Invasion

    October 13, 2023

    Black Lives Matter Group Deletes Tweet Showing Support for Hamas 

    October 13, 2023

    AOC Denounces NYC Rally Cheering Hamas Terrorism: ‘Unacceptable’

    October 13, 2023

    L.A. Prosecutors Call Out Soros-Backed Gascón for Silence on Israel

    October 13, 2023
  • Business

    Microsoft Bans Employees From Using ‘Chinese Propaganda’ Chatbot

    May 9, 2025

    OpenAI CEO Warns: ‘Not A Huge Amount Of Time’ Until China Overpowers American AI

    May 9, 2025

    Trump Announces First Post-Tariff Trade Deal

    May 8, 2025

    Electric Vehicle Sales Nosedive As GOP Takes Buzzsaw To Biden’s Mandate

    May 7, 2025

    Tyson Foods Announces It Will Bend The Knee To Trump Admin’s New Rules

    May 7, 2025
  • Finance

    Ending China’s De Minimis Exception Brings 3 Benefits for Americans

    April 17, 2025

    The Trump Tariff Shock Should Push Indonesia to Reform Its Economy

    April 17, 2025

    Tariff Talks an Opportunity to Reinvigorate the Japan-US Alliance

    April 17, 2025

    How China’s Companies Are Responding to the US Trade War

    April 16, 2025

    The US Flip-flop Over H20 Chip Restrictions 

    April 16, 2025
  • Tech

    Cruz Confronts Zuckerberg on Pointless Warning for Child Porn Searches

    February 2, 2024

    FTX Abandons Plans to Relaunch Crypto Exchange, Commits to Full Repayment of Customers and Creditors

    February 2, 2024

    Elon Musk Proposes Tesla Reincorporates in Texas After Delaware Judge Voids Pay Package

    February 2, 2024

    Tesla’s Elon Musk Tops Disney’s Bob Iger as Most Overrated Chief Executive

    February 2, 2024

    Mark Zuckerberg’s Wealth Grew $84 Billion in 2023 as Pedophiles Target Children on Facebook, Instagram

    February 2, 2024
  • More
    • Sports
    • Entertainment
    • Lifestyle
Patriot Now NewsPatriot Now News
Home»Health»Experts Raise New Questions About The Safety Of Anti-Alzheimer’s Drug Leqembi
Health

Experts Raise New Questions About The Safety Of Anti-Alzheimer’s Drug Leqembi

April 25, 2023No Comments5 Mins Read
Facebook Twitter Pinterest LinkedIn Tumblr Email
Experts Raise New Questions About The Safety Of Anti-Alzheimer’s Drug Leqembi
Share
Facebook Twitter LinkedIn Pinterest Email

Cells in an Alzheimer’s affected brain, with abnormal levels of the beta-amyloid protein clumping … [+] together to form plaques that collect between neurons and disrupt cell function. (National Institute on Aging, NIH via AP)

Associated Press

Medical experts are raising new questions about the safety of the anti-Alzheimer’s drug lecanemab, which is marketed as Leqembi by drugmakers Biogen
BIIB
and Eisai.

One study, which looked in detail at the death of a participant in a Leqembi research trial, suggests that people with a condition that affects as many as half of those with Alzheimer’s Disease may be at risk for severe, and even fatal, brain bleeding if they take the drug. And most troubling, the condition that endangers these people is extremely hard to diagnose. The result: Many of those who decide to take the drug won’t know how much risk they are taking.

At the same time, the independent research organization the Institute for Clinical and Economic Review (ICER) said in an April report that the drug “mildly slows the loss of cognition in patients with early Alzheimer’s disease.” But, it warned, “given the risks of brain swelling and bleeding, particularly when lecanemab is used outside of clinical trials…significant uncertainties remain as to whether the average benefits… will exceed its risks.”

Inadequate evidence

ICER’s conclusion: “Current evidence is not adequate to demonstrate a net health benefit of lecanemab when compared to supportive care alone.”

ICER’s concerns were buttressed by an autopsy of a woman who participated in the Leqembi trial and died from a severe brain hemorrhage.

Even before the FDA tentatively approved Leqembi last January, research trials showed that it could result in brain bleeds for some patients, but it generally considered those incidents minor. In its initial approval, the FDA recognized the risks of brain bleeds in patients with several conditions.

It said the drug may not be appropriate for people with amyloid-related imaging abnormalities (ARIA). Though ARIA, usually small brain bleeds or swelling, often has no symptoms, the agency noted that “life-threatening events rarely may occur.”

Similarly, patients taking blood thinners, such as those with heart disease, may be at higher risk for these Leqembi-related brain bleeds. And those with two copies of a gene variant called APOE4 also may have higher risk of brain swelling and bleeding. While small share of Alzheimer’s patients have the genetic variant, a large fraction take blood thinners because they also have heart disease, which is common among all older adults.

Autopsy results

But the careful study of one patient’s death appears to be strong evidence that yet another subset of patients, those with a condition known as cerebral amyloid angiopathy (CAA), may also be at higher risk for severe brain bleeds and strokes if they take Leqembi. With CAA, the same amyloid beta protein that attaches to brain cells in Alzheimer’s patients also weakens the walls of blood vessels in their brains. When drugs such as lecanemab remove the amyloid, the weakened vessels can leak, causing bleeding.

CAA may affect as many as half of all Alzheimer’s patients. Unfortunately, testing for CAA is complicated and expensive so the vast majority of people with condition don’t know they may be at elevated risk for this bleeding if they take an amyloid-busting drug such as lecanemab.

The analysis of the patient’s death was done by neuroscientists and pathologists at Vanderbilt University, Boston University, and the University of Florida. The results of the case report were first disclosed by Charles Piller of Science magazine.

Good news, and bad

Leqembi has excited researchers because it is the first that appears to slow the progression of Alzheimer’s Disease. Patients with early-stage Alzheimer’s (the only people in the trial) saw the disease progress about four months more slowly over the 18-month trial, though the benefits appeared to wane in the latter stages.

Like similar antibodies, this one significantly reduced the amount of the amyloid beta protein in the brains of users. Amyloid beta is closely associated with Alzheimer’s but it is not known if it causes the disease. The difference between Lecanamab and other drugs: It is the first of its class that provides clinical benefit for some patients.

Agonizing choices

The FDA plans a hearing in June to determine whether it should grant full approval of Leqembi. On a separate track, Medicare must decide whether it will pay for the drug, which makers Biogen and Esai plan to sell for a retail price of $26,500 for a year’s treatment. The drug must be taken by infusion for the patient’s lifetime, or as long as it appears to slow the condition.

Even if it gives full approval, FDA also must decide whether to add a warning label to inform physicians and patients of its risks, and it must figure out how restrictive that warning should be. Whatever FDA says, people living with early-stage Alzheimer’s and their families will face an agonizing choice.

Do you take a drug that may slow the disease’s progression, even if it costs $26,500 annually and no one knows how long it will be beneficial? Do you take it knowing it benefits some patients but may not help you? And do you take it if you don’t know whether you are at elevated risk of severe complications or even death from the drug?

See also  Mitch McConnell episode has important public health takeaway
AntiAlzheimers Drug Experts Leqembi questions raise safety
Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Related Posts

Business Experts Sound Alarm On DEI Initiatives In Corporate America

April 22, 2025

What Are The Consequences Of A Drug Possession Conviction?

March 19, 2025

China’s Retaliatory Tariffs Against Trump Are All Bark No Bite, Experts Say

February 8, 2025

Winter Skincare Routine Upgrades as Recommended by Experts

January 31, 2025
Add A Comment

Leave A Reply Cancel Reply

Top Posts

Sudden Rally in China Stocks Has Traders Scratching Their Heads

August 22, 2023

Wee Man Criticizes Snow White Movie, Says Little People’s Jobs Are Being Taken

July 22, 2023

Workers Worry as Sri Lanka Begins Reforming Labor Laws Again

June 7, 2023

Florida Panthers Restrict Ticket Sales to U.S. Residents to Keep Toronto Maple Leafs Fans Out

May 4, 2023
Don't Miss

Three Treatment Options To Consider

Lifestyle May 9, 2025

The most common cause of hair loss in men is male androgenetic alopecia (MAA), otherwise…

Microsoft Bans Employees From Using ‘Chinese Propaganda’ Chatbot

May 9, 2025

How Smart Mattresses Improve Sleep Quality For Couples

May 9, 2025

OpenAI CEO Warns: ‘Not A Huge Amount Of Time’ Until China Overpowers American AI

May 9, 2025
About
About

This is your World, Tech, Health, Entertainment and Sports website. We provide the latest breaking news straight from the News industry.

We're social. Connect with us:

Facebook Twitter Instagram Pinterest
Categories
  • Business (4,112)
  • Entertainment (4,220)
  • Finance (3,202)
  • Health (1,938)
  • Lifestyle (1,629)
  • Politics (3,084)
  • Sports (4,036)
  • Tech (2,006)
  • Uncategorized (4)
  • World (3,944)
Our Picks

China issues draft rules to regulate financial holding companies’ related transactions

August 30, 2022

Tory Lanez Breaks His Silence After Being Sentenced To 10 Years In Jail

August 12, 2023

Instacart to target valuation of up to $9.3 billion in IPO, source says

September 11, 2023
Popular Posts

Three Treatment Options To Consider

May 9, 2025

Microsoft Bans Employees From Using ‘Chinese Propaganda’ Chatbot

May 9, 2025

How Smart Mattresses Improve Sleep Quality For Couples

May 9, 2025
© 2025 Patriotnownews.com - All rights reserved.
  • Contact
  • Privacy Policy
  • Terms & Conditions

Type above and press Enter to search. Press Esc to cancel.